MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$470,732K
Net cash provided by
investing activities
$188,793K
Canceled cashflow
$281,939K
Net increase
(decrease) in cash and cash...
$31,017K
Canceled cashflow
$157,776K
Purchases of marketable
securities
$281,939K
Stock-based compensation
expense
$20,720K
Accrued expenses and
other liabilities
$12,651K
Accounts payable
$8,487K
Depreciation and
amortization expense
$416K
Proceeds from issuance of
common stock under espp
$201K
Proceeds from issuance of
common stock upon...
$58K
Net cash used in
operating activities
-$132,031K
Net cash (used in)
provided by financing...
-$25,745K
Canceled cashflow
$42,274K
Canceled cashflow
$259K
Other segment items
-$22,538K
Net loss
-$158,349K
Stock repurchase
$25,519K
Cash paid for taxes in
connection with rsu and psu...
$485K
Canceled cashflow
$22,538K
Income tax benefit
-$6,356K
Accretion of premium and
discounts on marketable...
$4,944K
Other assets
$2,939K
Prepaid expenses and
other current assets
$1,527K
Operating lease
liabilities
-$190K
Total research and
development expense
$137,578K
Total general and
administrative
$22,589K
Stock based
compensation
$20,720K
Back
Back
Cash Flow
source: myfinsight.com
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)